Wagner Klaus W. 4
4 · Inhibrx, Inc. · Filed Feb 18, 2021
Insider Transaction Report
Form 4
Inhibrx, Inc.INBX
Wagner Klaus W.
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-02-16$24.32/sh−156,474$3,805,448→ 234,709 total - Sale
Common Stock
2021-02-17$25.29/sh−19,559$494,647→ 215,150 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020.
- [F2]The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F3]The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.